Northera droxidopa: Extension study data

Top-line data from the 3-month, open-label phase of the Study 303 extension study in 75 patients showed that Northera significantly decreased OHQ composite scores by a mean of 3.2 units

Read the full 306 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE